MXPA04004396A - Metodos y composiciones para correccion de perturbaciones de conduccion cardiaca. - Google Patents

Metodos y composiciones para correccion de perturbaciones de conduccion cardiaca.

Info

Publication number
MXPA04004396A
MXPA04004396A MXPA04004396A MXPA04004396A MXPA04004396A MX PA04004396 A MXPA04004396 A MX PA04004396A MX PA04004396 A MXPA04004396 A MX PA04004396A MX PA04004396 A MXPA04004396 A MX PA04004396A MX PA04004396 A MXPA04004396 A MX PA04004396A
Authority
MX
Mexico
Prior art keywords
connexin
cells
cardiac
recombinant
correction
Prior art date
Application number
MXPA04004396A
Other languages
English (en)
Spanish (es)
Inventor
Randall J Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MXPA04004396A publication Critical patent/MXPA04004396A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
MXPA04004396A 2001-11-08 2004-05-07 Metodos y composiciones para correccion de perturbaciones de conduccion cardiaca. MXPA04004396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33735201P 2001-11-08 2001-11-08

Publications (1)

Publication Number Publication Date
MXPA04004396A true MXPA04004396A (es) 2004-08-11

Family

ID=23320214

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004396A MXPA04004396A (es) 2001-11-08 2004-05-07 Metodos y composiciones para correccion de perturbaciones de conduccion cardiaca.

Country Status (10)

Country Link
US (2) US7252819B2 (enExample)
EP (1) EP1453382A4 (enExample)
JP (1) JP2005527482A (enExample)
CN (1) CN1612691A (enExample)
AU (1) AU2002359371A1 (enExample)
BR (1) BR0214018A (enExample)
CA (1) CA2465476A1 (enExample)
IL (1) IL161862A0 (enExample)
MX (1) MXPA04004396A (enExample)
WO (1) WO2003039344A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161862A0 (en) * 2001-11-08 2005-11-20 Univ California Methods and compositions for correction of cardiac conduction disturbances
EP1503716A4 (en) * 2002-05-08 2007-07-04 Univ California SYSTEM AND METHOD FOR THE TREATMENT OF CARDIAC ARCHITECTURES WITH FIBROBLASTED CELLS
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
WO2003094697A2 (en) * 2002-05-08 2003-11-20 The Regents Of The University Of California Methods and compositions for correction of cardiac conduction disturbances
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US7794702B2 (en) * 2003-01-15 2010-09-14 The Trustees Of Columbia University In The City Of New York Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures
JP2007511291A (ja) * 2003-11-13 2007-05-10 シンフォニー メディカル， インコーポレイテッド 心臓の脂肪パッド内の神経伝達の改変による不整脈の制御
US8073538B2 (en) * 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
US20060128647A1 (en) * 2003-12-24 2006-06-15 Daniel Sigg Novel oligonucleotides and treating cardiac disorders by using the same
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
EP1768702A4 (en) * 2004-03-22 2008-08-13 Univ Johns Hopkins PREVENTION OF ARRHYTHMIA RELATED TO CELLULAR TRANSPLANTATION
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US20050277124A1 (en) 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
US20050283218A1 (en) * 2004-06-22 2005-12-22 Williams Michael S Implantable chamber for biological induction or enhancement of muscle contraction
US20060088503A1 (en) * 2004-10-13 2006-04-27 Vinod Sharma Cellular and genetic intervention to treat ventricular tachycardia
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US20080138416A1 (en) * 2006-06-13 2008-06-12 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
AU2007292923B2 (en) 2006-09-08 2013-10-03 Cardiopolymers, Inc. Intramyocardial patterning for global cardiac resizing and reshaping
US7787949B2 (en) * 2006-10-30 2010-08-31 Medtronic, Inc. Biological pacemaker compositions and systems incorporating interstitial cells of Cajal
WO2008127607A2 (en) * 2007-04-11 2008-10-23 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
EP2203129A4 (en) * 2007-10-15 2011-11-23 Univ Wake Forest Health Sciences METHOD AND COMPOSITIONS FOR PRINTING BIOCOMPATIBLE NANOROUS COMPOSITES FROM AUTOLOGOUS TISSUE
WO2009111755A2 (en) * 2008-03-07 2009-09-11 The Trustees Of Columbia University In The City Of New York Compensating for atrioventricular block using a nucleic acid encoding a sodium channel or gap junction protein
CN106178118A (zh) 2008-09-30 2016-12-07 加利福尼亚大学董事会 用于组织修复的使用细胞外基质的组合物和方法
US20110091427A1 (en) * 2009-10-02 2011-04-21 Baxter International Inc. Methods for treating a kidney injury
WO2012027514A2 (en) 2010-08-24 2012-03-01 The Regents Of The University Of California Compositions and methods for cardiac therapy
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2013036708A2 (en) 2011-09-07 2013-03-14 The Regents Of The University Of California Compositions and methods for tissue repair with extracellular matrices
US20130216495A1 (en) 2012-02-21 2013-08-22 Baxter Healthcare Sa Pharmaceutical composition comprising cd34+ cells
US10633625B2 (en) 2013-11-16 2020-04-28 Terumo Bct, Inc. Expanding cells in a bioreactor
JP2017505324A (ja) 2014-02-07 2017-02-16 ゴジョ・インダストリーズ・インコーポレイテッド 胞子及び他の生物に対する効力を有する組成物及び方法
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US12098385B2 (en) 2017-09-20 2024-09-24 The Regents Of The University Of California Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy
IL273448B2 (en) * 2017-09-20 2025-05-01 Univ California A gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy
JP7705950B2 (ja) 2021-03-23 2025-07-10 テルモ ビーシーティー、インコーポレーテッド 細胞を増殖する方法
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) * 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5030204A (en) 1988-09-28 1991-07-09 Advanced Cardiovascular Systems, Inc. Guiding catheter with controllable distal tip
WO1990010471A1 (en) 1989-03-06 1990-09-20 Angeion Corporation Method of providing a biological pacemaker
US5103821A (en) * 1989-03-06 1992-04-14 Angeion Corporation Method of providing a biological pacemaker
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5087243A (en) 1990-06-18 1992-02-11 Boaz Avitall Myocardial iontophoresis
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5551426A (en) 1993-07-14 1996-09-03 Hummel; John D. Intracardiac ablation and mapping catheter
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5489294A (en) 1994-02-01 1996-02-06 Medtronic, Inc. Steroid eluting stitch-in chronic cardiac lead
CA2183167A1 (en) 1994-12-13 1996-06-20 Peter K. Law Myoblast therapy for mammalian diseases
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5693029A (en) 1995-07-10 1997-12-02 World Medical Manufacturing Corporation Pro-cell intra-cavity therapeutic agent delivery device
US6415178B1 (en) * 1996-09-16 2002-07-02 Impulse Dynamics N.V. Fencing of cardiac muscles
AU2458597A (en) 1996-07-17 1998-02-09 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
CA2266033C (en) 1996-09-10 2005-11-08 Omrix Biopharmaceuticals S.A. Applicator device for applying a multiple component fluid
US5722403A (en) 1996-10-28 1998-03-03 Ep Technologies, Inc. Systems and methods using a porous electrode for ablating and visualizing interior tissue regions
US6059726A (en) * 1996-11-08 2000-05-09 The Regents Of The University Of California Method for locating the atrio-ventricular (AV) junction of the heart and injecting active substances therein
US6239117B1 (en) * 1997-02-13 2001-05-29 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating bladder smooth muscle tone
US6271211B1 (en) * 1997-02-13 2001-08-07 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating penile smooth muscle tone
US6086582A (en) 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US6110161A (en) * 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6238429B1 (en) * 1997-05-05 2001-05-29 Medtronic, Inc. Biologic cabling
EP1007631B2 (en) * 1997-07-14 2009-02-18 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
CA2225185A1 (en) * 1997-08-11 1999-02-11 Peter K. Law Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
EP1015042A1 (en) 1997-09-19 2000-07-05 Reprogenesis, Inc Improved hydrogel for tissue engineering
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
EP1563866B1 (en) * 1998-02-05 2007-10-03 Biosense Webster, Inc. Intracardiac drug delivery
US6360749B1 (en) 1998-10-09 2002-03-26 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US20010009986A1 (en) * 1999-02-23 2001-07-26 Cordis Webster, Inc. Steerable catheter for detecting and revascularizing ischemic myocardial tissue
WO2001066472A1 (en) 2000-03-06 2001-09-13 Tei Biosciences, Inc. Injectable bio-compatible material and methods of use
IL151605A0 (en) 2000-03-10 2003-04-10 Advanced Res & Tech Inst Cardiomyocyte cell populations, methods for obtaining the same and devices utilizing the same
DE10021627B4 (de) 2000-05-04 2009-11-19 Corlife Gbr (Vertretungsberechtigte Gesellschafter: Prof. Dr. Alex Haverich Verfahren zur Herstellung eines vaskularisierten bioartifiziellen Gewebes und zugehöriger Versuchsreaktor
US20020001577A1 (en) * 2000-06-30 2002-01-03 Axel Haverich Use of cells with the ability to generate excitation within a cell preparation
AU2001284695A1 (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001288807B2 (en) 2000-09-06 2007-07-19 Johns Hopkins University Cardiac arrhythmia treatment methods
US7294333B1 (en) 2000-10-20 2007-11-13 Genegrafts Ltd. Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
IL161862A0 (en) 2001-11-08 2005-11-20 Univ California Methods and compositions for correction of cardiac conduction disturbances
EP1503716A4 (en) 2002-05-08 2007-07-04 Univ California SYSTEM AND METHOD FOR THE TREATMENT OF CARDIAC ARCHITECTURES WITH FIBROBLASTED CELLS
WO2003094697A2 (en) 2002-05-08 2003-11-20 The Regents Of The University Of California Methods and compositions for correction of cardiac conduction disturbances
US20040106896A1 (en) 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US6932804B2 (en) * 2003-01-21 2005-08-23 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
JP2005524496A (ja) 2002-05-08 2005-08-18 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 非破壊性心伝導ブロック形成用システム及び方法
US7317950B2 (en) * 2002-11-16 2008-01-08 The Regents Of The University Of California Cardiac stimulation system with delivery of conductive agent

Also Published As

Publication number Publication date
US20030104568A1 (en) 2003-06-05
WO2003039344A2 (en) 2003-05-15
CA2465476A1 (en) 2003-05-15
US7494644B2 (en) 2009-02-24
BR0214018A (pt) 2005-04-19
AU2002359371A1 (en) 2003-05-19
US7252819B2 (en) 2007-08-07
IL161862A0 (en) 2005-11-20
WO2003039344A3 (en) 2003-12-31
US20080019953A1 (en) 2008-01-24
JP2005527482A (ja) 2005-09-15
CN1612691A (zh) 2005-05-04
EP1453382A2 (en) 2004-09-08
EP1453382A4 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
MXPA04004396A (es) Metodos y composiciones para correccion de perturbaciones de conduccion cardiaca.
WO2003094697A3 (en) Methods and compositions for correction of cardiac conduction disturbances
JP2005527482A5 (enExample)
IL144446A0 (en) Plasma protein matrices and methods for their preparation
NZ500253A (en) Osteoprotegerin binding proteins and receptors
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
AU7624798A (en) Inhibitors of interleukin-1 beta converting enzyme
EP1499187A4 (en) IMMUNOSTIMULANT OLIGORIBONUCLEOTIDES CONTAINING GUANINE AND URACILE
EP2110385A8 (en) Stabilized factor VIII with engineered disulfide bonds
AP0202540A0 (en) Inhibitors of interleukin -1B converting enyme.
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
NO20013801L (no) Ny karbonyl reduktase, gen derav og metoder for anvendelse av det samme
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
AU2009201827B2 (en) Nerve regeneration
AU2002356392A1 (en) Bone polypeptide-1
AU2003210053A1 (en) Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
IL196900A0 (en) Autologous t-cell vaccines compositions
AU2001259353A1 (en) Novel mutated form of arginine deiminase
AU5896098A (en) Inhibitors of interleukin-1beta converting enzyme
AU2901899A (en) 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
DE60230774D1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
GB2429211A (en) Feeder independent extended culture of embryonic stem cells
HK1040402A1 (zh) 使用乳粘素(lactadherin)或其變體的的方法及其組合物
WO1997046686A3 (en) Tumor necrosis factor-related polypeptide